Printer Friendly

Articles from M2 Pharma (October 26, 2018)

1-25 out of 25 article(s)
Title Author Type Words
Abbott unveils the next generation of influenza A & B and Strep A Assays on the ID NOW platform. 330
Alexion and Dicerna Forge Collaboration to Discover and Develop RNAi Therapies for Complement-Mediated Diseases. 765
Alexion Pharmaceuticals collaborates with Dicerna Pharmaceuticals. 175
BioArctic presents additional BAN2401 phase 2b study results in early Alzheimer's disease at the 2018 CTAD conference in Barcelona. Conference news 362
Cannabics Pharmaceuticals receives South Africa patent for core technology. 198
Charles River and Distributed Bio Enter Exclusive Partnership to Create an Integrated Antibody Discovery and Development Platform. 416
Cipher Pharmaceuticals introduces Brinavess in Canada. 175
Cortexyme Touts Phase 1 Data Demonstrating COR388 is Safe and Well Tolerated in Healthy Older Volunteers and Alzheimer's Patients. 922
Disarm Therapeutics Appoints Copeland, Iguchi to Board of Directors. 268
FDA Grants Priority Review for Ruxolitinib as a Treatment for Patients with Acute Graft-Versus-Host Disease. 510
H Lundbeck reports on clinical phase III study for Lu AF35700 in treatment-resistant schizophrenia. 214
Mati Therapeutics Expands Intellectual Property Portfolio with 114 Patents Issued. 455
Mayne Pharma acquires the halobetasol foam for plaque psoriasis, expanding US dermatology portfolio. 255
Merck's board approves higher Q4 dividend & expanded share repurchase plan. 131
Merz Presents Data Confirming the Long-Term Efficacy and Safety of Xeomin for Sialorrhea. 464
Nordic opens first clinical site in the US for the enrollment of patients under the pivotal PARADIGME trial. 268
Novaliq Touts Positive Topline Results for Its SEECASE Phase 2 Trial of NOV03 for the Treatment of Patients with Dry Eye Disease. 284
Nuvelution Pharma Appoints Ways as Chief Medical Officer. 262
Onxeo reports Q3 2018 consolidated revenues and provides business update. Financial report 424
Oyster Point Touts Positive Results from Two Separate Phase 2b Clinical Trials of the company's Investigational Treatments for Dry Eye Disease. 241
Recipharm announces manufacturing licence restriction by UK's MHRA at its Ashton-u-Lyne, UK facility. 239
Roche's Xofluza granted FDA approval. 175
TP Therapeutics and Almac Diagnostic Services Enter into Agreement to Develop Next-Generation Sequencing Pan-Cancer Companion Diagnostic. 600
vTv Therapeutics Presents Positive Data on the Effect of Azeliragon in Patients with Alzheimer's and Diabetes at the 11thClinical Trials on Alzheimer's Disease Conference. Conference news 583
West Pharmaceutical Services reports Q3 2018 financial results. Financial report 174

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters